#BIO22: The bear mar­ket may be maul­ing biotech stocks, but the fun­da­men­tals still look good to re­al es­tate de­vel­op­ers

The bear mar­ket that has cut the val­u­a­tions of biotech com­pa­nies has not yet af­fect­ed re­al es­tate de­vel­op­ment in life sci­ences, which con­tin­ues to ex­pe­ri­ence a “sus­tained boom,” said Matt Gard­ner, CBRE’s Amer­i­c­as life sci­ences leader.

“We’re ex­pe­ri­enc­ing a sus­tained boom as a re­sult of these dri­vers,” said Gard­ner. “The long IPO win­dow in biotech that went on for a few years. Tens of bil­lions of dol­lars flow­ing in­to the bioe­con­o­my from ad­vanced ma­te­ri­als and fu­ture foods. Ap­pli­ca­tions like bio­plas­tics are one of the biggest dri­vers, and it’s hap­pen­ing at large scale.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER